JP7773975B2 - 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用 - Google Patents

抗pd-l1単一ドメイン抗体ならびにその誘導体および使用

Info

Publication number
JP7773975B2
JP7773975B2 JP2022516220A JP2022516220A JP7773975B2 JP 7773975 B2 JP7773975 B2 JP 7773975B2 JP 2022516220 A JP2022516220 A JP 2022516220A JP 2022516220 A JP2022516220 A JP 2022516220A JP 7773975 B2 JP7773975 B2 JP 7773975B2
Authority
JP
Japan
Prior art keywords
single domain
seq
domain antibody
present application
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548066A5 (cg-RX-API-DMAC7.html
JP2022548066A (ja
Inventor
シュ,イーフォン
ヂャイ,ティエンハン
ユエン,ジージュン
ツン,アンディ
スン,ツォユエ・ジョアン
フアン,ウェイフォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheus Inc
Original Assignee
Biotheus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheus Inc filed Critical Biotheus Inc
Publication of JP2022548066A publication Critical patent/JP2022548066A/ja
Publication of JP2022548066A5 publication Critical patent/JP2022548066A5/ja
Priority to JP2025119680A priority Critical patent/JP2025163055A/ja
Application granted granted Critical
Publication of JP7773975B2 publication Critical patent/JP7773975B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2022516220A 2019-09-12 2020-09-07 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用 Active JP7773975B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025119680A JP2025163055A (ja) 2019-09-12 2025-07-16 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910863109.0 2019-09-12
CN201910863109.0A CN112480253B (zh) 2019-09-12 2019-09-12 一种抗pd-l1纳米抗体及其衍生物和用途
PCT/IB2020/058303 WO2021048725A1 (en) 2019-09-12 2020-09-07 Anti-pd-l1 single-domain antibody and derivatives and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025119680A Division JP2025163055A (ja) 2019-09-12 2025-07-16 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用

Publications (3)

Publication Number Publication Date
JP2022548066A JP2022548066A (ja) 2022-11-16
JP2022548066A5 JP2022548066A5 (cg-RX-API-DMAC7.html) 2023-09-08
JP7773975B2 true JP7773975B2 (ja) 2025-11-20

Family

ID=74866641

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516220A Active JP7773975B2 (ja) 2019-09-12 2020-09-07 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用
JP2025119680A Pending JP2025163055A (ja) 2019-09-12 2025-07-16 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025119680A Pending JP2025163055A (ja) 2019-09-12 2025-07-16 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用

Country Status (8)

Country Link
US (1) US12409233B2 (cg-RX-API-DMAC7.html)
EP (1) EP4028423A4 (cg-RX-API-DMAC7.html)
JP (2) JP7773975B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220064986A (cg-RX-API-DMAC7.html)
CN (3) CN115947846A (cg-RX-API-DMAC7.html)
AU (1) AU2020344237A1 (cg-RX-API-DMAC7.html)
CA (1) CA3150886A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048725A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025163055A (ja) * 2019-09-12 2025-10-28 普米斯生物技術(珠海)有限公司 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113461824A (zh) * 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 一种构建多特异性抗体的平台
WO2022042715A1 (zh) * 2020-08-31 2022-03-03 杭州九源基因工程有限公司 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
CN114106190B (zh) * 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN115124625B (zh) * 2021-03-24 2024-11-26 圣安生医股份有限公司 免疫调节及抗肿瘤相关纳米抗体、其核酸编码序列及应用
US11685784B2 (en) * 2021-03-24 2023-06-27 China Medical University Hospital Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same
CN117098780A (zh) * 2021-04-26 2023-11-21 天境生物科技(上海)有限公司 单域pd-l1抗体
CN115246884A (zh) * 2021-04-27 2022-10-28 上海君实生物医药科技股份有限公司 抗pd-l1单域抗体及其用途
CN114773485B (zh) * 2021-05-11 2024-05-17 江苏先声药业有限公司 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
TWI833227B (zh) * 2021-05-28 2024-02-21 大陸商和鉑醫藥(上海)有限責任公司 靶向pd-l1和cd73的特異性結合蛋白及其應用
CN116547006B (zh) * 2021-08-06 2024-09-20 贝达药业股份有限公司 抗pd-l1纳米抗体及其应用
CN116135884A (zh) * 2021-11-17 2023-05-19 普米斯生物技术(珠海)有限公司 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
CN116410314A (zh) * 2021-12-31 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型pdl1单域抗体的开发
CN114349861B (zh) * 2022-01-06 2023-07-07 华汤思圆 一种抗pd1纳米抗体及其制备方法和应用
CN114395046B (zh) * 2022-01-10 2023-06-23 宁夏医科大学 一种抗pd-1的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
CN115433281B (zh) * 2022-05-27 2023-09-12 华兰基因工程有限公司 一种抗pd-l1的人源化纳米抗体及其应用
CN117186223B (zh) * 2022-05-31 2024-08-09 明济生物制药(北京)有限公司 抗pd-l1抗体及编码其的核酸、制备方法和应用
WO2024036184A2 (en) * 2022-08-10 2024-02-15 International Aids Vaccine Initiative A human vh-based scaffold for the production of single domain antibodies and their use
EP4703382A1 (en) * 2023-04-20 2026-03-04 Kanglitai Biomedical (Qingdao) Co., Ltd. Anti-pd-l1 nanobody, preparation method therefor and use thereof
CN119234000B (zh) * 2023-09-25 2026-04-17 深圳湾实验室 可激活穿膜构建体和降解子
CN117229402A (zh) * 2023-09-27 2023-12-15 广州康盛生物科技股份有限公司 一种抗pd-l1蛋白的纳米抗体及其应用
CN117264054B (zh) * 2023-11-21 2024-02-06 中国人民解放军军事科学院军事医学研究院 靶向il-6的纳米抗体、组合物、方法及用途
CN121609799A (zh) * 2025-11-07 2026-03-06 深圳华大生命科学研究院 一种抗pd-l1的纳米抗体、含其的双特异性重组蛋白及其应用
CN122187981A (zh) * 2025-12-26 2026-06-12 首都医科大学 一种靶向人和食蟹猴pd-l1交叉结合的单域抗体14-d3及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
JP2018531039A (ja) 2015-07-31 2018-10-25 スジョウ・アルファマブ・カンパニー・リミテッドSuzhou Alphamab Co.,Ltd. プログラム死リガンド(pdl1)に対する単一ドメイン抗体およびその誘導体タンパク質
WO2019096121A1 (en) 2017-11-17 2019-05-23 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-l1
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
WO2019169212A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CN103965363B (zh) 2013-02-06 2021-01-15 上海白泽生物科技有限公司 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
CN107216389B (zh) * 2016-03-18 2022-03-29 和迈生物科技有限公司 抗pd-l1纳米抗体及其编码序列和用途
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CN107686520B (zh) * 2016-08-04 2023-01-03 信达生物制药(苏州)有限公司 抗pd-l1纳米抗体及其应用
CN109096396B (zh) * 2017-06-20 2022-01-04 华兰生物工程股份有限公司 一种抗pd-l1人源化纳米抗体及其应用
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN110835375B (zh) 2018-08-16 2021-04-06 上海洛启生物医药技术有限公司 一种抗pd-1/egfr双特异性抗体及其用途
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
TWI793395B (zh) 2019-01-25 2023-02-21 大陸商信達生物製藥(蘇州)有限公司 結合pd-l1和ox40的雙特異性抗體
CN109942712B (zh) 2019-04-01 2022-12-20 华博生物医药技术(上海)有限公司 抗pd-l1/vegf双功能抗体及其用途
CN110003333B (zh) 2019-04-12 2022-11-18 深圳普瑞金生物药业股份有限公司 多肽、pd-l1单域抗体、核苷酸序列及试剂盒
CN115947846A (zh) 2019-09-12 2023-04-11 普米斯生物技术(珠海)有限公司 一种抗pd-l1纳米抗体及其衍生物和用途
CN112646031B (zh) 2019-10-10 2021-12-07 天境生物科技(上海)有限公司 抗4-1bb纳米抗体及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
JP2018531039A (ja) 2015-07-31 2018-10-25 スジョウ・アルファマブ・カンパニー・リミテッドSuzhou Alphamab Co.,Ltd. プログラム死リガンド(pdl1)に対する単一ドメイン抗体およびその誘導体タンパク質
WO2019096121A1 (en) 2017-11-17 2019-05-23 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-l1
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
WO2019169212A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fei ZHANG et al.,Cell Discovery,2017年,3, Article number 17004,(pp. 1-12)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025163055A (ja) * 2019-09-12 2025-10-28 普米斯生物技術(珠海)有限公司 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用

Also Published As

Publication number Publication date
CN112480253A (zh) 2021-03-12
KR20220064986A (ko) 2022-05-19
JP2022548066A (ja) 2022-11-16
CN114502588A (zh) 2022-05-13
CA3150886A1 (en) 2021-03-18
CN115947846A (zh) 2023-04-11
JP2025163055A (ja) 2025-10-28
EP4028423A4 (en) 2023-09-20
WO2021048725A1 (en) 2021-03-18
US12409233B2 (en) 2025-09-09
CN112480253B (zh) 2022-09-20
CN114502588B (zh) 2024-12-10
US20220315658A1 (en) 2022-10-06
AU2020344237A1 (en) 2022-04-28
EP4028423A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
JP2025163055A (ja) 抗pd-l1単一ドメイン抗体ならびにその誘導体および使用
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
CA3007021C (en) Anti-pd-l1 single domain antibody and use thereof
US11292841B2 (en) Anti-PD-1 nano-antibody and application thereof
US11912770B2 (en) Blocking type PD-L1 single-domain camel antibody and application thereof
CN107216389B (zh) 抗pd-l1纳米抗体及其编码序列和用途
CN114195900B (zh) 一种抗4-1bb/pd-l1双特异性抗体及其用途
JP2021502407A (ja) 4−1bb抗体およびその製造方法と使用
CN114195894B (zh) 一种靶向4-1bb的抗体及其应用
US12600782B2 (en) Anti-PD-L1 and PD-L2 antibody and derivatives and use thereof
WO2025016458A1 (zh) 一种抗her2纳米抗体及其制备方法和应用
US20250345451A1 (en) Anti-pd-l1 single-domain antibody and derivatives and use thereof
JP7822652B2 (ja) 新規なpdl1単一ドメイン抗体の開発

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251110

R150 Certificate of patent or registration of utility model

Ref document number: 7773975

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350